U.S. Agrees To Buy 100 Million Doses Of Another COVID-19 Vaccine

Moderna plans to purchase 100 million doses of its experimental COVID-19 vaccine, developed with the National Institutes of Health, which is in late-stage trials. Unlike traditional vaccines, Moderna's uses mRNA to trigger an immune response. The U.S. government has a $1.5 billion contract with Moderna, allowing for the purchase of up to 400 million additional doses. Moderna is manufacturing the vaccine to ensure quick distribution upon approval. The Trump administration has similar deals with other companies, aiming for a vaccine by the end of 2020.

What is unique about Moderna's coronavirus vaccine compared to most traditional vaccines?

• It uses a live virus to trigger immunity.

• It introduces a small amount of virus into the body.

• It uses mRNA to stimulate an immune response.

• It is administered as a nasal spray.

How much is the U.S. government's contract with Moderna worth?

• $500 million

• $1.5 billion

• $2 billion

• $3 billion

What additional option does the U.S. government have in its contract with Moderna?

• To purchase 200 million more doses

• To purchase 400 million more doses

• To purchase 600 million more doses

• To purchase 800 million more doses

What is the goal of the Trump administration regarding COVID-19 vaccines?

• To have a vaccine ready by late 2021

• To have a vaccine ready by early 2022

• To have a vaccine ready by the end of 2020

• To have a vaccine ready by mid-2021

Which other entities has the Trump administration made similar vaccine deals with?

• Only AstraZeneca

• Various pharmaceutical companies

• Only Moderna

• Only Pfizer